ENvue Medical, Inc.
Healthcare sector | Medical Devices industry
Metrics for FEED
| Price | $1.14 |
|---|---|
| Shares Outstanding | 3.7M |
| All-Time Low | $0.99 |
| 52-Week Low | $0.99 |
Balance Statement Metrics
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $-0.1 |
| Net Tangible Assets / Share | $0.01 |
| Shares Outstanding Ave Change (Annual) | 43.87% |
| Shares Δ YoY | 103.71% |
| Avg CA Burn (Annual %) | -21.92% (as of 4-19-2026) |
| Avg CA Burn (Quarterly %) | 28.09% (as of 4-19-2026) |
Earning Metrics
| Max Earning Power / Share | $-16.74 |
|---|---|
| Adjusted Earning Power |
$-33.07
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
5.86%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 0 (as of 4-19-2026) |
| Avg EBITDA (5Q) | 171K (as of 4-19-2026) |
| Avg Net Income (5Y) | -6.8M (as of 4-19-2026) |
| Avg Net Income (5Q) | -4M (as of 4-19-2026) |
Indicators
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 4-19-2026 |
| Consecutive Years Paid | No | 4-19-2026 |
| Pays Dividend | No | 4-19-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 4-19-2026 |
| Net Income Positive | No | 4-19-2026 |
| Current Dividend Streak | No | 4-19-2026 |
Metric History Explorer
Pick a metric to view its history table and chart.
Tangible Book Value Per Share History
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $0.03 | 35K ($35,000) | 1.1M (1,100,413) |
| 2025-09-30 | Quarterly | $-1.43 | -1.4M ($-1,442,000) | 1M (1,011,086) |
| 2025-06-30 | Quarterly | $-4.66 | -3.7M ($-3,670,000) | 787.4K (787,359) |
| 2025-03-31 | Quarterly | $-54.18 | -4.1M ($-4,114,000) | 75.9K (75,929) |
| 2024-12-31 | Quarterly | $16.55 | 627K ($627,000) | 37.9K (37,894) |
| 2024-12-31 | Annual | $16.55 | 627K ($627,000) | 37.9K (37,894) |
| 2024-09-30 | Quarterly | $73.96 | 1.9M ($1,872,000) | 25.3K (25,312) |
| 2023-12-31 | Annual | $214.39 | 4M ($3,988,000) | 18.6K (18,602) |
| 2022-12-31 | Annual | $216.70 | 3.2M ($3,233,000) | 14.9K (14,919) |
| 2021-12-31 | Annual | $496.07 | 6.3M ($6,313,000) | 12.7K (12,726) |
Revenue History (Annual)
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 2.6M ($2,558,000) |
| 2023-12-31 | 2.3M ($2,283,000) |
| 2022-12-31 | 752K ($752,000) |
| 2021-12-31 | 1.7M ($1,695,000) |
Dividend Payments
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
Shares Outstanding Changes
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-04-17 | 3,700,908 | +2,612,716 |
Short Interest Changes
Latest short-interest change: 16,233 shares (0.45% of float) | Days to cover: 0.00
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-04-27 | 16,233 shares | -454,072 | -96.55% |
| 2026-04-17 | 470,305 shares | +381,597 | +430.17% |
| 2026-03-24 | 88,708 shares | -87,824 | -49.75% |
| 2026-03-12 | 176,532 shares | -174,142 | -49.66% |
| 2026-02-27 | 350,674 shares | -1,304,727 | -78.82% |
| 2026-02-11 | 1,655,401 shares | +1,441,161 | +672.69% |
Interesting Volume Days
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| 2026-04-16 | 289,130 | 1,088,192 | 26.57% | $1.60 |
| 2026-04-15 | 413,149 | 1,088,192 | 37.97% | $1.73 |
| 2026-04-02 | 355,113 | 1,088,192 | 32.63% | $1.96 |
| 2026-04-01 | 460,484 | 1,088,192 | 42.32% | $2.07 |
| 2026-03-31 | 433,478 | 1,088,192 | 39.83% | $2.38 |
| 2026-03-30 | 952,319 | 1,088,192 | 87.51% | $2.46 |
| 2026-03-27 | 2,428,617 | 1,088,192 | 223.18% | $2.43 |
| 2026-03-26 | 2,434,412 | 1,088,192 | 223.71% | $2.30 |
| 2026-03-25 | 21,914,699 | 1,088,192 | 2013.86% | $2.64 |
| 2026-03-24 | 129,340,590 | 1,088,192 | 11885.82% | $2.26 |
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. The company's product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also provides UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it offers PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. ENvue Medical, Inc. was incorporated in 2003 and is based in Tyler, Texas.